

Substitute for form 1449/PTO			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			<b>Application Number</b>	10/729,830-Conf. #8653	
			<b>Filing Date</b>	December 5, 2003	
			<b>First Named Inventor</b>	Florian Van der Mulbe	
			<b>Art Unit</b>	1636	
			<b>Examiner Name</b>	Jennifer A. Dunston	
<b>Sheet</b>	1	of	3	<b>Attorney Docket Number</b>	22122-00009-US1

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)				
	AN	US	3,906,092	09-16-1975	Hilleman et al	
	AO	US	5,663,153	09-02-1997	Hutcherson, et al.	
	AQ	US	5,965,720	10-12-1999	Gryaznov et al.	
	AR	US	6,239,116 B1	05-29-2001	Krieg, et al.	
	AS	US	6,322,967	11-27-2001	Parkin	
	AT	US	6,406,705	06-18-2002	Davis, et al.	
	AU	US	6,514,948	02-04-2003	Raz, et al.	
	AV	US	6,552,006	04-22-2003	Raz, et al.	
	AW	US	6,589,940	07-08-2003	Raz, et al.	
	AX	US	6,610,661	08-26-2003	Carson et al.	
	AY	US	6,664,066 B2	11-06-2003	Parks	
	AZ	US	7,208,478	04-24-2007	Carson et al.	
	AA1	US	7,276,489 B2	05-20-2004	Agrawal, et al.	
	AB1	US	2002 0132788 A1	09-19-2002	Lewis, et al.	
	AC1	US	2003 0143204 A1	07-31-2003	Lewis, et al.	
	AD1	US	2003 170273 A1	09-11-2003	O'Hagan, et al.	
	AE1	US	2003 0225016 A1	12-04-2003	Fearon, et al.	
	AF1	US	2004 005667 A1	01-08-2004	Ratti, et al.	
	AG1	US	2004 0106567 A1	06-03-2004	Hagstrom, et al.	
	AH1	US	2005 0037494 A1	02-17-2005	Hecker, et al.	
	AI1	US	2005 0059624 A1	03-17-2005	Hoerr et al.	
	AJ1	US	2005 0064596 A1	03-24-2005	Riemen, et al.	
	AK1	US	2005 0250723-A1	11-10-2005	Hoerr et al.	
	AL1	US	2006 0172968-A1	08-03-2006	Lipford et al.	
	AM1	US	2006 0241076 A1	10-26-2006	Uhlmann, et al.	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>3</sup>
		Country Code <sup>2</sup> -Number <sup>2</sup> -Kind Code <sup>2</sup> (if known)					
	BI	EP	0 839 912	05-06-1998	Instituut Voor Dierhouderij En		
	BJ	WO	1990/011092	10-04-1990	Vical Inc.		
	BK	WO	1993/014778	08-05-1993	Vical Inc		
	BL	WO	1997/041210	11-06/1997	Duke Univ.		
	BM	WO	2000/075304	12-14-2000	Aventis Pasteur		
	BN	WO	2001/021810 A1	03-29-2001	Aventis Pasteur		
	BO	WO	2001/093902	12-13-2001	Biosynexus Inc		

<b>Examiner Signature</b>	<b>Date Considered</b>
-------------------------------	----------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with a single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IPFW. Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			<b>Application Number</b>	10/729,830-Conf. #8653	
			<b>Filing Date</b>	December 5, 2003	
			<b>First Named Inventor</b>	Florian Van der Mulbe	
			<b>Art Unit</b>	1636	
			<b>Examiner Name</b>	Jennifer A. Dunston	
<b>Sheet</b>	2	of	3	<b>Attorney Docket Number</b>	22122-00009-US1

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>2</sup> -Number-Kind Code <sup>3</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>4</sup>
	BP	WO 2003/059381	07-24-2003	Curevac Gmbh		
	BQ	WO 2003/086280	10-23-2003	Coley Pharmaceutical Gmbh		
	BR	WO 2006/008154	01-26-2006	Curevac Gmbh et al.		
	BS	WO 2006/024518	03-09-2006	Curevac Gmbh et al.		

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T <sup>4</sup>
	CL	BOCZKOWSKI ET AL., "Dendritic Cells Pulsed With RNA are Potent antigen-Presenting Cells in Vitro and in Vivo", Journal of Experimental Medicine, 184, 465-472, 1996.				
	CM	BOCZKOWSKI ET AL., "Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells." Cancer Research, 60: 1028-1034, Feb 15, 2000.				
	CN	CHENG W F ET AL, "Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of mycobacterium tuberculosis heat shock protein 70 gene to an antigen gene" Journal Of Immunology, 166:6218-6226, May 2001				
	CO	CHENG, W. F. ET AL., "Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of mycobacterium tuberculosis heat shock protein 70 gene," J. Virol., 75(5):2368-2376, March 2001				
	CP	CONRY RM ET AL., "Characterization of a messenger RNA polynucleotide vaccine vector." Cancer Research 55(7):1397-1400, 1995				
	CQ	GRYAZNOV S M: "Oligonucleotide N3'->P5' phosphoramidates as potential therapeutic agents" Biochimica et Biophysica Acta. Gene Structure And Expression, 1489:131-140, 1999				
	CR	HEIDENREICH, O., ET AL., "Chemically modified RNA: approaches and applications." FASEB Journal, 7(1): 90-96, 1993				
	CS	HEISER ET AL., "Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA." J. Immunol. 166:2953-2960, March 2001.				
	CT	LOGING ET AL, "Identifying potential tumor markers and antigens by database mining and rapid expression screening." Genome Res. 10:1393-1402, 2000.				
	CU	SAENZ-BADILLOS ET AL., "RNA as a tumor vaccine: a review of the literature." Exp Dermatol. 10(3):143-54, June 2001.				
	CV	SCHIRRMACHER, V. et al., "Intra-pinna anti-tumor vaccination with self-replicating infectious RNA or with DNA encoding a model tumor antigen and a cytokine," Gene Therapy 7(13):1137-1147, July 2000				

<b>Examiner Signature</b>	<b>Date Considered</b>
---------------------------	------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(ii)) because that application was filed after June 30, 2003 or is available in the IPFW. \* Applicant's unique citation designation number (optional). \* See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901:04. \* Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \* For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \* Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \* Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			<b>Application Number</b>	10/729,830-Conf. #8653	
			<b>Filing Date</b>	December 5, 2003	
			<b>First Named Inventor</b>	Florian Van der Mulbe	
			<b>Art Unit</b>	1636	
			<b>Examiner Name</b>	Jennifer A. Dunston	
<b>Sheet</b>	3	of	3	<b>Attorney Docket Number</b>	22122-00009-US1

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	CW	SU ET AL., "Enhanced induction of telomerase-specific CD4(+) T cells using dendritic cells transfected with RNA encoding a chimeric gene product" Cancer Research. 62:5041-5048, September 2002		
	CX	WEISSMAN ET AL., "HIV gag mRNA transfection of dendritic cells (DC) delivers encoded antigen to MHC class I and II molecules, causes DC maturation, and induces a potent human in vitro primary immune response." J. Immunol. 165:4710-4717, October 2000.		
	CY	WOODBERRY T ET AL: "Immunogenicity of a human immunodeficiency virus (HIV) polytope vaccine containing multiple HLA A2 HIV CD8+ cytotoxic T-cell epitopes" Journal of Virology 73(7):5320-5325 July 1999		
	CZ	ZHOU ET AL. "RNA melanoma vaccine: induction of antitumor immunity by human glycoprotein 100 mRNA immunization." Human Gene Therapy 10: 2719-2724, 1999.		

<b>Examiner Signature</b>		<b>Date Considered</b>	
-------------------------------	--	----------------------------	--

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IPFW. <sup>2</sup> Applicant's unique citation designation number (optional). <sup>3</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901:04. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language Translation is attached.